116 related articles for article (PubMed ID: 22853442)
21. Cost-effectiveness of intensive adjuvant chemotherapy for high-risk breast cancer: is tailored and dose-escalated chemotherapy with growth factor support (GFS) more costly and less effective than marrow-supported high-dose chemotherapy - results from a randomized study.
Kellokumpu-Lehtinen P; Bergh J; Salminen E; Wiklund T; Lehtinen S; Aronen P; Sintonen H
Acta Oncol; 2007; 46(2):146-52. PubMed ID: 17453362
[TBL] [Abstract][Full Text] [Related]
22. Cost-effectiveness of letrozole in the extended adjuvant treatment of women with early breast cancer.
El Ouagari K; Karnon J; Delea T; Talbot W; Brandman J
Breast Cancer Res Treat; 2007 Jan; 101(1):37-49. PubMed ID: 16821085
[TBL] [Abstract][Full Text] [Related]
23. Polychemotherapy for early breast cancer: results from the international adjuvant breast cancer chemotherapy randomized trial.
Adjuvant Breast Cancer Trials Collaborative Group
J Natl Cancer Inst; 2007 Apr; 99(7):506-15. PubMed ID: 17405995
[TBL] [Abstract][Full Text] [Related]
24. Adjuvant therapy for breast cancer.
NIH Consens Statement; 2000 Nov 1-3; 17(4):1-35. PubMed ID: 11512506
[TBL] [Abstract][Full Text] [Related]
25. Development of a method to determine the cost of breast cancer treatment with chemotherapy at Groote Schuur Hospital, Cape Town, South Africa.
Guzha NT; Thebe T; Butler N; Valodia PN
S Afr Med J; 2020 Mar; 110(4):296-301. PubMed ID: 32657741
[TBL] [Abstract][Full Text] [Related]
26. Cost-effectiveness analysis of 5 years of postoperative adjuvant tamoxifen therapy for Korean women with breast cancer: retrospective cohort study of the Korean breast cancer society database.
Yang JJ; Park SK; Cho LY; Han W; Park B; Kim H; Lee KS; Hahn SK; Cho SI; Ahn SH; Noh DY;
Clin Ther; 2010 Jun; 32(6):1122-38. PubMed ID: 20637966
[TBL] [Abstract][Full Text] [Related]
27. Resource use and costs associated with different states of breast cancer.
Lidgren M; Wilking N; Jönsson B; Rehnberg C
Int J Technol Assess Health Care; 2007; 23(2):223-31. PubMed ID: 17493308
[TBL] [Abstract][Full Text] [Related]
28. Health care costs for treatment of disseminated breast cancer.
Dahlberg L; Lundkvist J; Lindman H
Eur J Cancer; 2009 Jul; 45(11):1987-91. PubMed ID: 19398326
[TBL] [Abstract][Full Text] [Related]
29. [Standard treatment cost of female breast cancer at different TNM stages].
Li H; Huang Y; Huang R; Li JY
Zhonghua Zhong Liu Za Zhi; 2013 Dec; 35(12):946-50. PubMed ID: 24506967
[TBL] [Abstract][Full Text] [Related]
30. Cost-effectiveness of letrozole versus tamoxifen as initial adjuvant therapy in hormone receptor-positive postmenopausal women with early-stage breast cancer.
Delea TE; Karnon J; Sofrygin O; Thomas SK; Papo NL; Barghout V
Clin Breast Cancer; 2007 Jun; 7(8):608-18. PubMed ID: 17592673
[TBL] [Abstract][Full Text] [Related]
31. [Impact of the chemotherapy protocols for metastatic breast cancer on the treatment cost and the survival time of 371 patients treated in three hospitals of the Rhone-Alpes region].
Paviot BT; Bachelot T; Clavreul G; Jacquin JP; Mille D; Rodrigues JM
Bull Cancer; 2009 Oct; 96(10):929-40. PubMed ID: 19696006
[TBL] [Abstract][Full Text] [Related]
32. Costs and quality of life of multiple sclerosis in Switzerland.
Kobelt G; Berg J; Lindgren P; Gerfin A; Lutz J
Eur J Health Econ; 2006 Sep; 7 Suppl 2():S86-95. PubMed ID: 17310338
[TBL] [Abstract][Full Text] [Related]
33. The economic burden of metastatic breast cancer: a U.S. managed care perspective.
Montero AJ; Eapen S; Gorin B; Adler P
Breast Cancer Res Treat; 2012 Jul; 134(2):815-22. PubMed ID: 22684273
[TBL] [Abstract][Full Text] [Related]
34. Self-evaluation of Adjuvant Chemotherapy-Related Adverse Effects by Patients With Breast Cancer.
Montemurro F; Mittica G; Cagnazzo C; Longo V; Berchialla P; Solinas G; Culotta P; Martinello R; Foresto M; Gallizioli S; Calori A; Grasso B; Volpone C; Bertola G; Parola G; Tealdi G; Giuliano PL; Aglietta M; Ballari AM
JAMA Oncol; 2016 Apr; 2(4):445-52. PubMed ID: 26720497
[TBL] [Abstract][Full Text] [Related]
35. Societal cost of subcutaneous and intravenous trastuzumab for HER2-positive breast cancer - An observational study prospectively recording resource utilization in a Swedish healthcare setting.
Olofsson S; Norrlid H; Karlsson E; Wilking U; Ragnarson Tennvall G
Breast; 2016 Oct; 29():140-6. PubMed ID: 27498127
[TBL] [Abstract][Full Text] [Related]
36. [Delays in treatment of breast cancer: experience of an expert center of the Assistance Publique-Hôpitaux de Paris (AP-HP)].
Revaux A; Laas E; Chopier J; Thomassin-Naggara I; Touboul E; Antoine M; Gligorov J; Darai E
Gynecol Obstet Fertil; 2014 Sep; 42(9):585-90. PubMed ID: 24993654
[TBL] [Abstract][Full Text] [Related]
37. Chemotherapy administration: modelling the costs of alternative protocols.
Haywood P; de Raad J; van Gool K; Haas M; Gallego G; Pearson SA; Faedo M; Ward R
Pharmacoeconomics; 2012 Dec; 30(12):1173-86. PubMed ID: 23148697
[TBL] [Abstract][Full Text] [Related]
38. Cost of corneal transplantation for the Quebec health care system.
Roussy JP; Aubin MJ; Brunette I; Lachaine J
Can J Ophthalmol; 2009 Feb; 44(1):36-41. PubMed ID: 19169311
[TBL] [Abstract][Full Text] [Related]
39. Estimation of lung cancer diagnosis and treatment costs based on a patient-level analysis in Catalonia (Spain).
Corral J; Espinàs JA; Cots F; Pareja L; Solà J; Font R; Borràs JM
BMC Health Serv Res; 2015 Feb; 15():70. PubMed ID: 25889153
[TBL] [Abstract][Full Text] [Related]
40. Cost-benefit of the 21-gene breast cancer recurrence score assay for patients in Singapore.
de Lima Lopes G; Chien R; Hornberger J
Breast J; 2013; 19(2):220-1. PubMed ID: 23320386
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
